genedrive

genedrive is a UK-based pharmacogenetic testing company with a slogan of "Advancing Diagnostics to the Point Of Care." The company is focused on developing and commercialising a rapid and simple-to-use point-of-need pharmacogenetic platform for the diagnosis of genetic variants, specifically targeting emergency healthcare settings. The use of pharmacogenetics allows for personalized and more effective medication choices by considering individual genetics. The company has launched two flagship products, Genedrive® MT-RNR1 ID Kit and Genedrive® CYP2C19 ID Kit, both of which have been developed and validated in collaboration with NHS partners. The Genedrive® MT-RNR1 ID Kit is a world-first product that enables clinicians to make quick decisions on antibiotic use in neonatal intensive care units within 26 minutes, thus ensuring timely and vital care without adverse effects. On the other hand, the Genedrive® CYP2C19 ID Kit empowers clinicians to make informed treatment decisions for stroke patients based on their individual ability to metabolize the antiplatelet clopidogrel. Founded in 2016, genedrive is a pioneering company at the forefront of point-of-care pharmacogenetic testing, addressing critical needs in emergency healthcare. Overall, genedrive's innovative approach to point-of-care pharmacogenetic testing and its collaborations with NHS partners showcase a promising trajectory in the biomedical industry, particularly in personalized medicine and rapid diagnostics.